Disney to pay $10 million to settle US claim of allowing unlawful collection of children's data-February 2024-www.financetom.com

Disney to pay $10 million to settle US claim of allowing unlawful collection of children's data

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Disney to pay $10 million to settle US claim of allowing unlawful collection of children's data

Sep 2, 2025 12:23 PM

WASHINGTON, Sept 2 (Reuters) - Walt Disney ( DIS ) will

pay $10 million to settle U.S. Federal Trade Commission

allegations that the company unlawfully allowed personal data to

be collected from children who viewed kid-directed videos on

YouTube without notifying parents or obtaining their consent,

the FTC said on Tuesday.

Previous page： Boeing's Calhoun says its board is ready to make decisions for succession Next page： --CoreWeave Offers $5.75 Per Share for Core Scientific, Bloomberg Says

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Boeing's Calhoun says its board is ready to make decisions for succession

Jun 4, 2024

BERLIN (Reuters) - Boeing's ( BA ) board is prepared to make decisions as the planemaker's Chief Executive David Calhoun is set to step down at the end of the year, he told Reuters on Wednesday, adding that the decision on his successor is up to the board. The board is prepared to make their decisions, they have time to...

--CoreWeave Offers $5.75 Per Share for Core Scientific, Bloomberg Says

Jun 4, 2024

08:44 AM EDT, 06/04/2024 (MT Newswires) -- Price: 6.7000, Change: +1.83, Percent Change: +37.58 ...

BridgeBio Pharma Phase 2 Trial of Infigratinib Shows 'Continued Well-Tolerated Safety Profile'; Starts Phase 3 Trial Enrollment

Jun 4, 2024

08:45 AM EDT, 06/04/2024 (MT Newswires) -- BridgeBio Pharma ( BBIO ) said late Monday its group 5 dose escalation in a phase 2 trial of infigratinib, an investigational therapy to treat children with achondroplasia, a growth deficiency, is showing a continued well-tolerated safety profile. The trial, Propel 2, demonstrated a mean increase in annualized height velocity, with a +2.51...

BRIEF-Russel Metals Receives Regulatory Clearance On Samuel Acquisition

Jun 4, 2024

June 4 (Reuters) - Russel Metals Inc ( RUSMF ): * RUSSEL METALS RECEIVES REGULATORY CLEARANCE ON SAMUEL ACQUISITION Source text for Eikon: Further company coverage: ...